Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1

Journal of Clinical Immunology

Volumn 27, Issue 1, 2007, Pages 117-130

  Li, Ning ^a   Qin, Hanjun ^b   Li, Xiaozhu ^c   Zhou, Chunxia ^a   Wang, Dongmei ^a   Ma, Wenbo ^a   Lin, Chen ^a   Zhang, Youhui ^a   Wang, Shengdian ^c   Zhang, Shuren ^a  

^a CANCER HOSPITAL   (China)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

B7 H1; Cell vaccine; Fc; Prostate antigen; SLC

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; B7 H1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SECONDARY LYMPHOID TISSUE CHEMOKINE 3P IMMUNOGLOBULIN FC FRAGMENT VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FUSION GENE; GENETIC TRANSFECTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SPLEEN CELL; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C57BL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; SURVIVAL RATE; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 33846858157     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-006-9053-z     Document Type: Article

References (37)

1. Tarassoff CP, Arlen PM, Gulley JL: Therapeutic vaccines for prostate cancer. Oncologist 11(5):451-462, 2006
2. Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S: Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol Lett 99(1):85-93, 2005
3. Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S: Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 117(3):419-430, 2006
4. Fong L, Small EJ: Immunotherapy for prostate cancer. Curr Urol Rep 7(3):239-246, 2006
5. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM: Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166(9):5366-5373, 2001
6. Willimann K, Legler DF, Loetscher M, Roos RS, Delgado MB, Clark-Lewis I, Baggiolini M, Moser B: The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28:2025-2034, 1998
7. Cyster JG: Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189:447-450, 1999
8. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Striter RM, Dubinett SM: Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10:2891-2901, 2004
9. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT: A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 95:258-263, 1998
10. Ravetch JV: Fc receptors: rubor redux. Cell 78:553-560, 1994
11. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S: Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371-380, 1999
12. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89, 1998
13. Rothstein DM, Sayegh MH: T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 196:85-108, 2003
14. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765-772, 1996
15. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8(5):773-780, 1996
16. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33(10):2706-2716, 2003
17. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141-151, 1999
18. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319-322, 2001
19. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192(7):1027-1034, 2000
20. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261-268, 2001
21. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L: Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 197(9):1083-1091, 2003
22. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257-1266, 2003
23. Lu J, Celis E: Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 62(20):5807-5812, 2002
24. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1):21-26, 1996
25. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE: A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 96(4):1553-1558, 1999
26. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks: Suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26(2):111-117, 2005
27. Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3(8):630-641, 2003
28. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296-306, 2005
29. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe AH: PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101(29):10691-10696, 2004
30. Hu HM, Winter H, Urba WJ, Fox BA: Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 165(8):4246-4253, 2000
31. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10(5):588-594, 1998
32. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 188(12):2357-2368, 1998
33. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186(1):65-70, 1997
34. Toes RE, Ossendorp F, Offringa R, Melief CJ: CD4 T cells and their role in antitumor immune responses. J Exp Med 189(5):753-756, 1999
35. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.J Exp Med 187(5):693-702, 1998
36. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR: Crosspresentation: A general mechanism for CTL immunity and tolerance. Immunol Today 19(8):368-373, 1998
37. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR: HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171(8):4054-4061, 2003